251 related articles for article (PubMed ID: 28853492)
1. Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant.
Ohanyan T; Schoepke N; Eirefelt S; Hoey G; Koopmann W; Hawro T; Maurer M; Metz M
Acta Derm Venereol; 2018 Jan; 98(1):26-31. PubMed ID: 28853492
[TBL] [Abstract][Full Text] [Related]
2. Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU).
Tsianakas A; Zeidler C; Riepe C; Borowski M; Forner C; Gerss J; Metz M; Staubach P; Raap U; Kaatz M; Urban M; Luger TA; Ständer S
Acta Derm Venereol; 2019 Apr; 99(4):379-385. PubMed ID: 30653242
[TBL] [Abstract][Full Text] [Related]
3. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
4. Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.
Tebas P; Spitsin S; Barrett JS; Tuluc F; Elci O; Korelitz JJ; Wagner W; Winters A; Kim D; Catalano R; Evans DL; Douglas SD
AIDS; 2015 May; 29(8):931-9. PubMed ID: 25915168
[TBL] [Abstract][Full Text] [Related]
5. Neurokinin 1 receptor antagonists exhibit peripheral effects in prurigo nodularis including reduced ERK1/2 activation.
Agelopoulos K; Rülander F; Dangelmaier J; Lotts T; Osada N; Metze D; Luger TA; Loser K; Ständer S
J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):2371-2379. PubMed ID: 31442331
[TBL] [Abstract][Full Text] [Related]
6. Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial.
Ständer S; Kwon P; Hirman J; Perlman AJ; Weisshaar E; Metz M; Luger TA;
J Am Acad Dermatol; 2019 May; 80(5):1395-1402. PubMed ID: 30894279
[TBL] [Abstract][Full Text] [Related]
7. Substance P Antagonist Aprepitant Shows no Additive Effect Compared with Standardized Topical Treatment Alone in Patients with Atopic Dermatitis.
Lönndahl L; Holst M; Bradley M; Killasli H; Heilborn J; Hall MA; Theodorsson E; Holmberg J; Nordlind K
Acta Derm Venereol; 2018 Mar; 98(3):324-328. PubMed ID: 29182791
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.
Barrett JS; Spitsin S; Moorthy G; Barrett K; Baker K; Lackner A; Tulic F; Winters A; Evans DL; Douglas SD
J Transl Med; 2016 May; 14(1):148. PubMed ID: 27230663
[TBL] [Abstract][Full Text] [Related]
9. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.
Keller M; Montgomery S; Ball W; Morrison M; Snavely D; Liu G; Hargreaves R; Hietala J; Lines C; Beebe K; Reines S
Biol Psychiatry; 2006 Feb; 59(3):216-23. PubMed ID: 16248986
[TBL] [Abstract][Full Text] [Related]
10. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy.
Ständer S; Siepmann D; Herrgott I; Sunderkötter C; Luger TA
PLoS One; 2010 Jun; 5(6):e10968. PubMed ID: 20532044
[TBL] [Abstract][Full Text] [Related]
11. Substance P and the Neurokinin-1 Receptor: The New CRF.
Schank JR; Heilig M
Int Rev Neurobiol; 2017; 136():151-175. PubMed ID: 29056150
[TBL] [Abstract][Full Text] [Related]
12. Neurokinin Receptor 1 (NK1R) Antagonist Aprepitant Enhances Hematoma Clearance by Regulating Microglial Polarization via PKC/p38MAPK/NFκB Pathway After Experimental Intracerebral Hemorrhage in Mice.
Jin P; Deng S; Sherchan P; Cui Y; Huang L; Li G; Lian L; Xie S; Lenahan C; Travis ZD; Zhang JH; Gong Y; Tang J
Neurotherapeutics; 2021 Jul; 18(3):1922-1938. PubMed ID: 34244927
[TBL] [Abstract][Full Text] [Related]
13. A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults.
Tebas P; Tuluc F; Barrett JS; Wagner W; Kim D; Zhao H; Gonin R; Korelitz J; Douglas SD
PLoS One; 2011; 6(9):e24180. PubMed ID: 21931661
[TBL] [Abstract][Full Text] [Related]
14. The neuropeptide substance P regulates aldosterone secretion in human adrenals.
Wils J; Duparc C; Cailleux AF; Lopez AG; Guiheneuf C; Boutelet I; Boyer HG; Dubessy C; Cherifi S; Cauliez B; Gobet F; Defortescu G; Ménard JF; Louiset E; Lefebvre H
Nat Commun; 2020 May; 11(1):2673. PubMed ID: 32471973
[TBL] [Abstract][Full Text] [Related]
15. Neurokinin-1 receptor inhibition reverses ischaemic brain injury and dementia in bilateral common carotid artery occluded rats: possible mechanisms.
Kaur J; Sharma S; Sandhu M; Sharma S
Inflammopharmacology; 2016 Aug; 24(4):133-43. PubMed ID: 27380492
[TBL] [Abstract][Full Text] [Related]
16. Modeling and simulation approach to support dosing and study design requirements for treating HIV-related neuropsychiatric disease with the NK1-R antagonist aprepitant.
Barrett JS; Bajaj G; McGuire J; Wu D; Spitsin S; Moorthy G; Zhao X; Tebas P; Evans DL; Douglas SD
Curr HIV Res; 2014; 12(2):121-31. PubMed ID: 24862330
[TBL] [Abstract][Full Text] [Related]
17. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts.
Muñoz M; Berger M; Rosso M; Gonzalez-Ortega A; Carranza A; Coveñas R
Int J Oncol; 2014 Jan; 44(1):137-46. PubMed ID: 24190675
[TBL] [Abstract][Full Text] [Related]
19. Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial.
Yosipovitch G; Ständer S; Kerby MB; Larrick JW; Perlman AJ; Schnipper EF; Zhang X; Tang JY; Luger T; Steinhoff M
J Am Acad Dermatol; 2018 May; 78(5):882-891.e10. PubMed ID: 29462657
[TBL] [Abstract][Full Text] [Related]
20. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S
JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]